Institute of Cardiovascular Sciences We are leaders in cardiovascular research, including atrial fibrillation and heart failure, thrombosis and haemostasis, and vascular biology.
News Bridging science and creativity: a reflective session on liver health Birmingham researchers hosted a unique event that brought together liver disease patients, researchers, charity partners, and an artist in residence.
News Fontan circulation link to changes in genetic code may lead to new treatment for heart conditions
15 November 2022 Researchers make miniature ‘bone marrows in a dish’ to improve anti-cancer treatments The organoids provide a micro-environment that can accept and support the survival of cells from patients with blood malignancies
20 October 2022 Dr Gill Lowe appointed as national haematology lead at NIHR Dr Gill Lowe in the Institute of Cardiovascular Sciences, University of Birmingham has been appointed National Haematology Specialty Lead
14 October 2022 New £30M research injection to improve treatment of inflammatory diseases Renewed National Institute for Health and Care Research Birmingham Biomedical Research Centre continue funds for developments around inflammatory diseases
13 October 2022 Dr Melanie Madhani receives Japan Society for the Promotion of Science Fellowship Award Dr Melanie Madhani has been internationally recognised by the Japan Society for the Promotion of Science (JSPS) for her outstanding research.
28 September 2022 Targeting mast cells could be beneficial to treat Covid-19 patients New research uncovers the role of mast cells in Covid-19, and mast cell stabilizers could be efficient and safe in tackling the blockage of blood vessels.
16 September 2022 Professor of Metabolism and Inflammation awarded £828K British Heart Foundation Research Fellowship Professor Claudio Mauro has been awarded a British Heart Foundation Senior Research Fellowship towards research in immunometabolism in atherosclerosis.
01 September 2022 Anticlotting hope after rare genetic defect discovery New research with families in Chile looking at a rare genetic defect suggests that new, more powerful drugs to prevent dangerous clotting would be safe.